Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study
Conclusions
Mortality risk in PsA in Sweden was about 10% higher than in the general population, driven by excess comorbidity and with increased risks mainly in women and patients with longer disease duration. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - March 12, 2024 Category: Rheumatology Authors: Exarchou, S., Di Giuseppe, D., Klingberg, E., Sigurdardottir, V., Wedren, S., Lindström, U., Turesson, C., Jacobsson, L. T. H., Askling, J., Wallman, J. K. Tags: Editor's choice, ARD, Psoriatic arthritis Source Type: research
Effectiveness of longstanding exercise therapy compared with usual care for people with rheumatoid arthritis and severe functional limitations: a randomised controlled trial
Conclusion
Longstanding, supervised exercise therapy was more effective than usual care in people with RA and severe functional limitations.
Trial registration number
Netherlands Trial Register (NL8235), included in the International Clinical Trial Registry Platform (https://trialsearch.who.int/Trial2.aspx?TrialID=NL8235). (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - March 12, 2024 Category: Rheumatology Authors: Teuwen, M. M. H., van Weely, S. F. E., Vliet Vlieland, T. P. M., van Wissen, M. A. T., Peter, W. F., den Broeder, A. A., van Schaardenburg, D., van den Hout, W. B., Van den Ende, C. H. M., Gademan, M. G. J. Tags: ARD Lay summaries, ARD, Rheumatoid arthritis Source Type: research
Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis
Conclusions
Lower BMI and evidence of lower adiposity based on adipokine profiles were associated with a superior response to TNFi compared with triple therapy. There was no difference between treatments among overweight/obese participants. The results support TNFi being a particularly important therapeutic among normal/underweight patients, with implications for clinical decisions and trial design. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - March 12, 2024 Category: Rheumatology Authors: Baker, J. F., ODell, J. R., England, B. R., Giles, J. T., Newcomb, J. A., George, M. D., Thiele, G., Moreland, L., Bridges, S. L., Curtis, J. R., Mikuls, T. R. Tags: ARD, Rheumatoid arthritis Source Type: research
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot study)
Conclusion
While JAKi overall were not associated with more treatment discontinuations for AEs, subgroup analyses suggest varying patterns with specific JAKi, such as tofacitinib, compared with TNFi. However, these observations should be interpreted cautiously, given the observational study design. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - March 12, 2024 Category: Rheumatology Authors: Aymon, R., Mongin, D., Bergstra, S. A., Choquette, D., Codreanu, C., De Cock, D., Dreyer, L., Elkayam, O., Huschek, D., Hyrich, K. L., Iannone, F., Inanc, N., Kearsley-Fleet, L., KOCA, S. S., Kvien, T. K., Leeb, B. F., Lukina, G., Nordström, D. C. Tags: Open access, ARD, Rheumatoid arthritis Source Type: research
Morris Ziff
We, rheumatologists, practise in an era when the study of rheumatic diseases and the care of affected patients are rooted in rigorous scientific investigation. This was not the case before the mid-20th century, when Dr Morris Ziff and a few other Pillars of Rheumatology pioneered the application of rigorous basic and clinical science to a nascent field, in which affected people were often regarded as hopeless and incurable. It is important to recall that rheumatology is a very young discipline. Before 1937, there were only six major US centres of rheumatology, and their focus was mainly on disease description. Other than a...
Source: Annals of the Rheumatic Diseases - March 12, 2024 Category: Rheumatology Authors: Cohen, P., Ziff, D., Lipsky, P. E. Tags: ARD Heroes and pillars of rheumatology Source Type: research
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023
The Advances in Targeted Therapies meets annually, convening experts in the field of rheumatology to both provide scientific updates and identify existing scientific gaps within the field. To review the major unmet scientific needs in rheumatology. The 23rd annual Advances in Targeted Therapies meeting convened with more than 100 international basic scientists and clinical researchers in rheumatology, immunology, infectious diseases, epidemiology, molecular biology and other specialties relating to all aspects of immune-mediated inflammatory diseases. We held breakout sessions in five rheumatological disease-specific group...
Source: Annals of the Rheumatic Diseases - March 12, 2024 Category: Rheumatology Authors: Winthrop, K. L., Mease, P., Kerschbaumer, A., Voll, R. E., Breedveld, F. C., Smolen, J. S., Gottenberg, J.-E., Baraliakos, X., Kiener, H. P., Aletaha, D., Isaacs, J. D., Buch, M. H., Crow, M. K., Kay, J., Crofford, L., van Vollenhoven, R. F., Ospelt, C., Tags: ARD Viewpoint Source Type: research
Obinutuzumab in patients with Sjogrens disease immunised against rituximab
Patients treated with rituximab (RTX) may develop antidrug antibodies (ADAb) leading to inefficacy and infusion reactions,1 more frequently in systemic autoimmune diseases (sAID) than in rheumatoid arthritis.2 In those immunised patients, targeting B-cells with another anti-CD20 molecule is an option. Obinutuzumab (OBZ) is another anti-CD20 antibody used in lymphoproliferative malignancies.3 Few studies reported its efficacy and safety in patients with sAID,4–6 and none reported documented anti-RTX immunisation. Thus, it remains unknown if OBZ can be safe and efficient in patients with ADAb to RTX. This retrospective...
Source: Annals of the Rheumatic Diseases - February 15, 2024 Category: Rheumatology Authors: Pezot, M., Nocturne, G., Belkhir, R., Henry, J., Pavy, S., Seror, R., Mariette, X., Bitoun, S. Tags: ARD Letter Source Type: research
Prevalence of clinically meaningful antiphospholipid antibodies in patients with systemic lupus erythematosus varies by race and ethnicity
The presence of antiphospholipid antibodies (aPLs), highly pathogenic autoantibodies that may trigger thrombosis and serious pregnancy complications, can influence the course of systemic lupus erythematosus (SLE) and contribute to organ damage.1 2 Reports of the frequency of aPLs in patients with SLE are highly variable, ranging from 11% to 86% of patients, but generally quoted as 25%–40%.3 4 Determination of the prevalence of aPLs is challenged by lack of standardisation of assays to measure lupus anticoagulant (LAC) and lack of standardisation of cut-off values in reports of aPL positivity for anti-cardiolipin (aCL...
Source: Annals of the Rheumatic Diseases - February 15, 2024 Category: Rheumatology Authors: Yelnik, C. M., Xie, X., Guerra, M. M., Costedoat-Chalumeau, N., Khosroshahi, A., Kamen, D. L., Schwartz, N., Katz, P., Minett, M., Amoss, R. T., Fu, A., Guettrot-Imbert, G., Lazaro, E., Le Guern, V., Oates, J., Dall'Era, M., Yazdany, J., Molto, A., Kim, M Tags: ARD Letter Source Type: research
Time to address the challenge of difficult to treat psoriatic arthritis: results from an international survey
Psoriatic arthritis (PsA) is a highly heterogeneous disease with involvement of multiple tissues, underpinned by complex pathogenesis. Despite major improvements in the range and availability of efficacious treatment options, including biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs),1 significant clinical unmet needs remain, with overall low rates of achievement of disease remission.2 Furthermore, a divergence of response is often seen between tissues, particularly skin and joints, or poor response in the presence of comorbidities, including mental health and other factors, leading to a...
Source: Annals of the Rheumatic Diseases - February 15, 2024 Category: Rheumatology Authors: Marzo-Ortega, H., Harrison, S. R., Nagy, G., Machado, P. M., McGonagle, D. G., Aydin, S. Z., Almodovar-Gonzalez, R., Bautista-Molano, W., Gossec, L., Lubrano, E., Nash, P., Pimentel Santos, F., Soriano, E. R., Siebert, S. Tags: ARD Letter Source Type: research
Elderly woman with polyarthritis, heliotrope-like rash, lymphadenopathy and polyneuropathy
A woman in her 80s manifested polyarthritis with anti-citrullinated-protein antibody positivity in April 2021, leading to a diagnosis of rheumatoid arthritis. Although she had taken prednisolone, sulfasalazine and methotrexate, her joint inflammation persisted. In September 2021, she presented facial flushing, black pigmentation on fingers and oedematous erythema of face and eyelid like heliotrope rash (figure 1A). However, muscular weakness and tenderness were not observed, and laboratory test demonstrated no elevated levels of muscular enzymes and myositis-specific/myositis-associated autoantibodies including anti-ARS, M...
Source: Annals of the Rheumatic Diseases - February 15, 2024 Category: Rheumatology Authors: Abe, N., Bohgaki, M., Kasahara, H. Tags: ARD, Images in rheumatology Source Type: research
Validation of a new glucocorticoid-specific Patient-Reported Outcome Questionnaire (the Steroid PRO)
Conclusions
The Steroid PRO is a 15-item, valid and reliable scale for measuring the impact of glucocorticoid therapy in people with rheumatic diseases. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - February 15, 2024 Category: Rheumatology Authors: Bridgewater, S., Ndosi, M., Dawson, J., Richards, P., Silverthorne, C., Dures, E., Goodman, S. M., Hill, C., Mackie, S. L., Robson, J. C. Tags: Open access, ARD, Epidemiology Source Type: research
OA susceptibility in mice is partially mediated by the gut microbiome, is transferrable via microbiome transplantation and is associated with immunophenotype changes
Conclusion
The gut microbiome is responsible in part for OA protection in MRL mice and is transferrable by microbiome transplantation. Transplantation induces resting systemic immunophenotyping changes that correlate with OA protection. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - February 15, 2024 Category: Rheumatology Authors: Prinz, E., Schlupp, L., Dyson, G., Barrett, M., Szymczak, A., Velasco, C., Izda, V., Dunn, C. M., Jeffries, M. A. Tags: ARD, Osteoarthritis Source Type: research
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry
Conclusion
VEXAS syndrome is associated with a high incidence of serious infections, especially in older patients carrying the p.Met41Val mutation and treated with JAK inhibitors. The high frequency of atypical infections, especially in patients without treatment, may indicate an intrinsic immunodeficiency. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - February 15, 2024 Category: Rheumatology Authors: de Valence, B., Delaune, M., Nguyen, Y., Jachiet, V., Heiblig, M., Jean, A., Riescher Tuczkiewicz, S., Henneton, P., Guilpain, P., Schleinitz, N., Le Guenno, G., Lobbes, H., Lacombe, V., Ardois, S., Lazaro, E., Langlois, V., Outh, R., Vinit, J., Martellos Tags: ARD, Autoinflammatory disorders Source Type: research
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögrens syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial
Conclusions
These data show preliminary efficacy and favourable safety of remibrutinib in a phase 2 trial for SjS. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - February 15, 2024 Category: Rheumatology Authors: Dörner, T., Kaul, M., Szanto, A., Tseng, J.-C., Papas, A. S., Pylvaenaeinen, I., Hanser, M., Abdallah, N., Grioni, A., Santos Da Costa, A., Ferrero, E., Gergely, P., Hillenbrand, R., Avrameas, A., Cenni, B., Siegel, R. M. Tags: Open access, ARD Sjo[x0308]gren ' s syndrome Source Type: research
Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial
Conclusions
Rituximab dosed for B cell repopulation results in fewer clinical relapses than when dosed for a rise in ANCA level in maintenance of remission for ANCA vasculitis. Overall safety was equivalent; SAEs due to COVID-19 and rituximab exposure were higher with the B cell strategy.
Trial registration number
NCT02749292. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - February 15, 2024 Category: Rheumatology Authors: Zonozi, R., Cortazar, F. B., Jeyabalan, A., Sauvage, G., Nithagon, P., Huizenga, N. R., Rosenthal, J. M., Sipilief, A., Cosgrove, K., Laliberte, K. A., Rhee, E. P., Pendergraft,, W. F., Niles, J. L. Tags: ARD Lay summaries, ARD, Vasculitis Source Type: research
